Vor Biopharma (VOR) shares were up more than 36% in Wednesday premarket trading after the company said its collaborator RemeGen has achieved the primary endpoint in a phase 3 clinical study in China evaluating telitacicept in adults with primary Sjogren's disease.

The study achieved the primary endpoint of improving disease activity measured by a reduction in EULAR Sjogren's syndrome disease activity index, with telitacicept demonstrating a favorable safety profile, Vor Biopharma said.

In June, Vor Biopharma was granted global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept under an exclusive license agreement with RemeGen.

RemeGen plans to submit a biologics license application to the National Medical Products Administration in China for primary Sjogren's disease, which would be telitacicept's fourth approved indication in China, Vor Biopharma said.